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➤ Although tamoxifen has been the standard of care for the adjuvant treatment of early-stage breast cancer in postmenopausal women for many years, the drug is associated with an increased risk of vaginal discharge and bleeding, proliferative endometrial abnormalities, and endometrial cancer, in part because of its partial estrogen-agonist effects. Furthermore, many tumors eventually become resistant to tamoxifen.
➤ in postmenopausal women, the majority of circulating estrogen is derived peripherally from aromatase-mediated conversion of testosterone. Third-generation aromatase inhibitors (Ais) inhibit peripheral aromatase activity and decrease plasma estrogen levels to less than 20% of pretreatment levels.
➤ compared with remaining on tamoxifen, switching from tamoxifen after two or three years to treatment with an Ai is associated with improved survival, decreased cancer recurrence, and a decreased incidence of contralateral breast cancer, but it also is associated with an increased incidence of arthralgia, bone loss, and variable effects on lipid metabolism. (American cancer society, 2008) . After initial treatment with surgery and radiotherapy, most patients are offered adjuvant endocrine therapy to reduce the risk of recurrent or contralateral breast cancer. Tamoxifen has been the mainstay of adjuvant endocrine therapy for hormonesensitive early-stage breast cancer since the 1980s. However, the development of newer agents, such as third-generation aromatase inhibitors (Ais), has increased the options available for adjuvant therapy for postmenopausal women with breast cancer (D'Hondt & Piccart, 2004; grana, 2003; michaud, 2005; Palmieri & Perez, 2003) .
Oncology nurses, in addition to providing clinical care, are an important source of information and guidance, from initial diagnosis through treatment and follow-up, to patients with breast cancer (Halkett, Arbon, scutter, & Borg, 2006; Harwood, 2004; rosenzweig, 2006) . Patients look to oncology nurses for information about treatment options and guidance regarding the potential impact of treatment on their overall health and quality of life (QOl), as well as for support in dealing with the emotional consequences of treatment (Halkett et al.) . nurses often are the first point of contact in addressing
